Safety analysis of high-dose ulinastatin combined with piperacillin and tazobactam sodium in the treatment of severe pneumonia complicated with respiratory failure
Objective:To explore the efficacy and safety of high-dose ulinastatin combined with piperacillin and tazobactam sodium in the treatment of severe pneumonia complicated with respiratory failure.Methods:The clinical data of 94 patients with severe pneumonia combined with respiratory failure who received ulinastatin combined with piperacillin and tazobactam sodium in our hospital from February 2021 to April 2023 were retrospectively collected.According to the dose of ulinastatin used in treatment,patients were divided into low-dose ulinastatin(100,000 units of ulinastatin combined with piperacillin and tazobactam sodium,47 cases)and high-dose ulinastatin(200,000 units of ulinastatin combined with piperacillin and tazobactam sodium,47 cases).The levels of inflammatory factors,lung function,blood gas indexes and adverse reactions of the two groups were analyzed and compared.Results:After 2 weeks of treatment,the levels of PCT and CRP in both groups were lower than before treatment,and the levels of PCT and CRP in high-dose group were significantly lower than those in control group(P<0.05).After 2 weeks of treatment,the levels of FEV1 and FVC in both groups were higher than before treatment,and the levels of FEV1 and FVC in high-dose group were significantly higher than those in control group(P<0.05).After 2 weeks of treatment,the levels of SaO2 and OI in both groups were higher than before treatment,and the levels of SaO2 and OI in high-dose group were significantly higher than those in control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Compared with low-dose ulinastatin,high-dose ulinastatin combined with piperacillin and tazobactam sodium in the treatment of severe pneumonia complicated with respiratory failure can reduce systemic inflammatory response,improve lung function and blood gas indexes,and does not significantly increase adverse reactions,with high safety.
Severe pneumoniaRespiratory failurePiperacillin tazobactam sodiumUlinastatinLarge dosesSecurity
NETL
NSTL
万方数据
